Smilow Multiple Myeloma and Gammopathies Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473
Natalia Neparidze, MD
Hematologic Oncology, Hematology
Telehealth is available
Patient type treated
Child, Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine, Hematology (Internal Medicine)
, and Medical Oncology
Titles
- Associate Professor of Internal Medicine (Hematology)
- Research Leader, Myeloma Program, Hematology
Education & Training
- FellowshipYale University (2010)
- ResidencyHospital of St Raphael, New Haven, CT (2007)
- Post Doctoral Research AssociateYale University (2004)
- MDAieti Medical School (2000)
Additional Information
Board Certifications
- AB of Internal Medicine, Medical Oncology (2010, recertified: 2020)
- AB of Internal Medicine, Hematology (Internal Medicine) (2010, recertified: 2020)
Publications
- Patell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS. Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. Thrombosis And Haemostasis 2020, 120: 1725-1732. PMID: 32828072, PMCID: PMC7869034, DOI: 10.1055/s-0040-1715837.
- Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.
- Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.
- Crawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report. Clinical Case Reports 2022, 10: e05583. PMID: 35340637, PMCID: PMC8933632, DOI: 10.1002/ccr3.5583.
- Muradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, ahead-of-print: 1-8. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.
- Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s238. DOI: 10.1016/s2152-2650(24)00965-0.
- Neparidze N, Godara A, Godara D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. MM-416 Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s555-s556. DOI: 10.1016/s2152-2650(24)01678-1.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study. Healthcare 2024, 12: 1660. PMID: 39201218, PMCID: PMC11353550, DOI: 10.3390/healthcare12161660.
- Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare 2024, 12: 1587. PMID: 39201146, PMCID: PMC11354118, DOI: 10.3390/healthcare12161587.
- Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
- Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.
- Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.
- Theprungsirikul P, Liu Y, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study. Blood 2023, 142: 7364. DOI: 10.1182/blood-2023-186985.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma. Blood 2023, 142: 7353. DOI: 10.1182/blood-2023-178893.
- Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.
- Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.
- Muradashvili T, Yu M, Neparidze N. P-098 Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s88-s89. DOI: 10.1016/s2152-2650(23)01716-0.
- Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.
- Theprungsirikul P, Neparidze N. Impact of the COVID-19 pandemic on treatment approaches of multiple myeloma. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i6.3912.
- Mirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel. Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Gonsalves W, Neparidze N, Allred J, Kumar S, Reid J, Shapiro G, Costello B, Piekarz R, Baz R, Devarakonda S. A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood 2022, 140: 7315-7316. DOI: 10.1182/blood-2022-164966.
- Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma. Blood 2022, 140: 5270-5271. DOI: 10.1182/blood-2022-164741.
- Di M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
- Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
- Parikh RB, Takvorian SU, Vader D, Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA, Investigators T. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal Of The National Cancer Institute 2021, 114: 571-578. PMID: 34893865, PMCID: PMC9002283, DOI: 10.1093/jnci/djab225.
- Neparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.
- Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1930. PMCID: PMC8701834, DOI: 10.1182/blood-2021-153625.
- Calip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. Blood 2021, 138: 4121. DOI: 10.1182/blood-2021-152774.
- Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.
- Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.
- Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.
- Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.
- Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott E, Hoering A, Durie B, Usmani S, Orlowski R. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood 2020, 136: 20-21. DOI: 10.1182/blood-2020-143180.
- Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.
- Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.
- Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agentsGiri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.
- Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.
- Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.
- Gonsalves W, Devarakonda S, Baz R, Neparidze N, Adjei A, Kunos C, Kumar S. Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood 2019, 134: 3160. DOI: 10.1182/blood-2019-123399.
- Zeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States. Blood 2019, 134: 646. DOI: 10.1182/blood-2019-127398.
- Zeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study. Blood 2019, 134: 116. DOI: 10.1182/blood-2019-126643.
- Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.
- Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.
- Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 2019, 5 PMID: 31013254, PMCID: PMC6629164, DOI: 10.1172/jci.insight.127807.
- Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
- Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, Bagale A, Terzi YK, Gbyli R, Wang X, Fu X, Gao Y, Zhao J, Podoltsev N, Xu M, Neparidze N, Wong E, Torres R, Bruscia EM, Kluger Y, Manz MG, Flavell RA, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications 2019, 10: 366. PMID: 30664659, PMCID: PMC6341122, DOI: 10.1038/s41467-018-08166-x.
- Cho H, Costa L, Davies F, Neparidze N, Vij R, Feng Y, Teterina A, Fritsch E, Wenger M, Kaufman J. Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma. Blood 2018, 132: 597. DOI: 10.1182/blood-2018-99-114960.
- Giri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.
- Juthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood 2018, 132: 5810. DOI: 10.1182/blood-2018-99-119418.
- Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3: e98259. PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.
- Azmy V, Neparidze N. Hyperbilirubinemia following lenalidomide administration. Clinical Case Reports 2018, 6: 875-877. PMID: 29744077, PMCID: PMC5930194, DOI: 10.1002/ccr3.1471.
- Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, Bar N, Halene S, Neparidze N, Parker TL, Burns AJ, Dumont A, Yao X, Chaar CIO, Connors JM, Bale AE, Lee AI. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Advances 2017, 1: 1224-1237. PMID: 29296762, PMCID: PMC5728544, DOI: 10.1182/bloodadvances.2017005249.
- Tainsh LT, Coady PA, Sinard JH, Neparidze N, Meskin SW, Adelman RA, Chow J. Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. Cornea 2017, 36: 372-374. PMID: 28079685, DOI: 10.1097/ico.0000000000001139.
- Cecchini M, Rose MG, Wong EY, Neparidze N. The implementation of electronic hematology consults at a VA hospital. Blood 2016, 127: 1610-1611. PMID: 26809506, PMCID: PMC4807425, DOI: 10.1182/blood-2015-09-672113.
- Neparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction. Blood 2014, 124: 4857. DOI: 10.1182/blood.v124.21.4857.4857.
- Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clinical Advances In Hematology And Oncology 2014, 12: 358-71. PMID: 25003566.
- Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2012, 121: 423-430. PMID: 23100308, PMCID: PMC3548165, DOI: 10.1182/blood-2012-06-435503.
- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges.Neparidze N and Dhodapkar, MV. Chapter. Natural Killer T Cells. Cancer Drug Discovery and Development 2012, pp 153-167
- Neparidze N, Dhodapkar M. Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges. Cancer Drug Discovery And Development 2011, 153-167. DOI: 10.1007/978-1-4614-0613-6_9.
- Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.
- Neparidze N, Dhodapkar MV. Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans. Annals Of The New York Academy Of Sciences 2009, 1174: 61-67. PMID: 19769737, PMCID: PMC2782771, DOI: 10.1111/j.1749-6632.2009.04931.x.
- NEPARIDZE N, KRIZ N, ORNSTEIN DL. Hetastarch haemophilia. Haemophilia 2009, 15: 976-979. PMID: 19473419, DOI: 10.1111/j.1365-2516.2009.02023.x.
- Dhodapkar MV, Neparidze N. NKT cells in p53 deficiency. Blood 2009, 113: 6268-6269. PMID: 19541831, DOI: 10.1182/blood-2009-03-211318.
- Song PI, Neparidze N, Armstrong C, Ansel J, Park Y, Abraham T, Harten B, Zivony A. Human Keratinocytes Express Functional CD14 and Toll-Like Receptor 4. Journal Of Investigative Dermatology 2002, 119: 424-432. PMID: 12190866, DOI: 10.1046/j.1523-1747.2002.01847.x.
Departments and Programs
Locations
Smilow Multiple Myeloma and Gammopathies Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473
Titles
- Associate Professor of Internal Medicine (Hematology)
- Research Leader, Myeloma Program, Hematology
Education & Training
- FellowshipYale University (2010)
- ResidencyHospital of St Raphael, New Haven, CT (2007)
- Post Doctoral Research AssociateYale University (2004)
- MDAieti Medical School (2000)
Additional Information
Board Certifications
- AB of Internal Medicine, Medical Oncology (2010, recertified: 2020)
- AB of Internal Medicine, Hematology (Internal Medicine) (2010, recertified: 2020)
Publications
- Patell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS. Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. Thrombosis And Haemostasis 2020, 120: 1725-1732. PMID: 32828072, PMCID: PMC7869034, DOI: 10.1055/s-0040-1715837.
- Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.
- Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.
- Crawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report. Clinical Case Reports 2022, 10: e05583. PMID: 35340637, PMCID: PMC8933632, DOI: 10.1002/ccr3.5583.
- Muradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, ahead-of-print: 1-8. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.
- Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s238. DOI: 10.1016/s2152-2650(24)00965-0.
- Neparidze N, Godara A, Godara D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. MM-416 Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s555-s556. DOI: 10.1016/s2152-2650(24)01678-1.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study. Healthcare 2024, 12: 1660. PMID: 39201218, PMCID: PMC11353550, DOI: 10.3390/healthcare12161660.
- Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare 2024, 12: 1587. PMID: 39201146, PMCID: PMC11354118, DOI: 10.3390/healthcare12161587.
- Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
- Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.
- Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.
- Theprungsirikul P, Liu Y, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study. Blood 2023, 142: 7364. DOI: 10.1182/blood-2023-186985.
- Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma. Blood 2023, 142: 7353. DOI: 10.1182/blood-2023-178893.
- Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.
- Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.
- Muradashvili T, Yu M, Neparidze N. P-098 Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s88-s89. DOI: 10.1016/s2152-2650(23)01716-0.
- Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.
- Theprungsirikul P, Neparidze N. Impact of the COVID-19 pandemic on treatment approaches of multiple myeloma. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i6.3912.
- Mirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel. Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Gonsalves W, Neparidze N, Allred J, Kumar S, Reid J, Shapiro G, Costello B, Piekarz R, Baz R, Devarakonda S. A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood 2022, 140: 7315-7316. DOI: 10.1182/blood-2022-164966.
- Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma. Blood 2022, 140: 5270-5271. DOI: 10.1182/blood-2022-164741.
- Di M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
- Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
- Parikh RB, Takvorian SU, Vader D, Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA, Investigators T. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal Of The National Cancer Institute 2021, 114: 571-578. PMID: 34893865, PMCID: PMC9002283, DOI: 10.1093/jnci/djab225.
- Neparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.
- Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1930. PMCID: PMC8701834, DOI: 10.1182/blood-2021-153625.
- Calip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. Blood 2021, 138: 4121. DOI: 10.1182/blood-2021-152774.
- Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.
- Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.
- Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.
- Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.
- Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott E, Hoering A, Durie B, Usmani S, Orlowski R. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood 2020, 136: 20-21. DOI: 10.1182/blood-2020-143180.
- Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.
- Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.
- Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agentsGiri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.
- Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.
- Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.
- Gonsalves W, Devarakonda S, Baz R, Neparidze N, Adjei A, Kunos C, Kumar S. Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood 2019, 134: 3160. DOI: 10.1182/blood-2019-123399.
- Zeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States. Blood 2019, 134: 646. DOI: 10.1182/blood-2019-127398.
- Zeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study. Blood 2019, 134: 116. DOI: 10.1182/blood-2019-126643.
- Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.
- Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.
- Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 2019, 5 PMID: 31013254, PMCID: PMC6629164, DOI: 10.1172/jci.insight.127807.
- Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
- Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, Bagale A, Terzi YK, Gbyli R, Wang X, Fu X, Gao Y, Zhao J, Podoltsev N, Xu M, Neparidze N, Wong E, Torres R, Bruscia EM, Kluger Y, Manz MG, Flavell RA, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications 2019, 10: 366. PMID: 30664659, PMCID: PMC6341122, DOI: 10.1038/s41467-018-08166-x.
- Cho H, Costa L, Davies F, Neparidze N, Vij R, Feng Y, Teterina A, Fritsch E, Wenger M, Kaufman J. Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma. Blood 2018, 132: 597. DOI: 10.1182/blood-2018-99-114960.
- Giri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.
- Juthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood 2018, 132: 5810. DOI: 10.1182/blood-2018-99-119418.
- Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3: e98259. PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.
- Azmy V, Neparidze N. Hyperbilirubinemia following lenalidomide administration. Clinical Case Reports 2018, 6: 875-877. PMID: 29744077, PMCID: PMC5930194, DOI: 10.1002/ccr3.1471.
- Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, Bar N, Halene S, Neparidze N, Parker TL, Burns AJ, Dumont A, Yao X, Chaar CIO, Connors JM, Bale AE, Lee AI. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Advances 2017, 1: 1224-1237. PMID: 29296762, PMCID: PMC5728544, DOI: 10.1182/bloodadvances.2017005249.
- Tainsh LT, Coady PA, Sinard JH, Neparidze N, Meskin SW, Adelman RA, Chow J. Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. Cornea 2017, 36: 372-374. PMID: 28079685, DOI: 10.1097/ico.0000000000001139.
- Cecchini M, Rose MG, Wong EY, Neparidze N. The implementation of electronic hematology consults at a VA hospital. Blood 2016, 127: 1610-1611. PMID: 26809506, PMCID: PMC4807425, DOI: 10.1182/blood-2015-09-672113.
- Neparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction. Blood 2014, 124: 4857. DOI: 10.1182/blood.v124.21.4857.4857.
- Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clinical Advances In Hematology And Oncology 2014, 12: 358-71. PMID: 25003566.
- Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2012, 121: 423-430. PMID: 23100308, PMCID: PMC3548165, DOI: 10.1182/blood-2012-06-435503.
- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges.Neparidze N and Dhodapkar, MV. Chapter. Natural Killer T Cells. Cancer Drug Discovery and Development 2012, pp 153-167
- Neparidze N, Dhodapkar M. Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges. Cancer Drug Discovery And Development 2011, 153-167. DOI: 10.1007/978-1-4614-0613-6_9.
- Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.
- Neparidze N, Dhodapkar MV. Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans. Annals Of The New York Academy Of Sciences 2009, 1174: 61-67. PMID: 19769737, PMCID: PMC2782771, DOI: 10.1111/j.1749-6632.2009.04931.x.
- NEPARIDZE N, KRIZ N, ORNSTEIN DL. Hetastarch haemophilia. Haemophilia 2009, 15: 976-979. PMID: 19473419, DOI: 10.1111/j.1365-2516.2009.02023.x.
- Dhodapkar MV, Neparidze N. NKT cells in p53 deficiency. Blood 2009, 113: 6268-6269. PMID: 19541831, DOI: 10.1182/blood-2009-03-211318.
- Song PI, Neparidze N, Armstrong C, Ansel J, Park Y, Abraham T, Harten B, Zivony A. Human Keratinocytes Express Functional CD14 and Toll-Like Receptor 4. Journal Of Investigative Dermatology 2002, 119: 424-432. PMID: 12190866, DOI: 10.1046/j.1523-1747.2002.01847.x.
Departments and Programs
Locations
Smilow Multiple Myeloma and Gammopathies Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473
Smilow Multiple Myeloma and Gammopathies Program
Smilow Cancer Hospital at North Haven
6 Devine Street
North Haven, CT 06473
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473